Comparative PK, Safety, Tolerability, Immunogenicity, and PD Profile Study of TUR03 and Soliris in Healthy Participants

NCT05863442 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Soliris 300 MG in 30 ML Injection
DRUG: TUR03 300 MG in 30 ML Injection

Sponsor

Turgut Ardika PTY LTD